S. Aliberti

Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group

Giovanni Grignani, Lorenzo D’Ambrosio, Ymera Pignochino et al. · The Lancet Oncology · 2018 · 89 citations · Full text

Non-resectable Bone, Surgical Oncology, Medicine +6

PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models

Ymera Pignochino, Federica Capozzi, Lorenzo D’Ambrosio et al. · Molecular Cancer · 2017 · 69 citations · Full text

Phase 2 trial of two courses of cyclophosphamide and etoposide for relapsed high‐risk osteosarcoma patients

Massimo Berger, Giovanni Grignani, Stefano Ferrari et al. · Cancer · 2009 · 62 citations

Osteosarcoma Patients, Medicine, Progression‐free Survival +13

Impact of a risk-based follow-up in patients affected by gastrointestinal stromal tumour

Lorenzo D’Ambrosio, Erica Palesandro, Paola Boccone et al. · European Journal of Cancer · 2017 · 37 citations

Surgical Oncology, Risk-based Follow-up, Cancer Risk +13

Aspergillus Serologic Findings and Clinical Outcomes in Patients With Bronchiectasis

Jennifer S. Pollock, Pieter Goeminne, S. Aliberti et al. · CHEST Journal · 2024 · 15 citations · Full text